Creating new targeted therapies for advanced prostate cancer
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype
This study is testing a new type of treatment for metastatic prostate cancer that uses special antibodies to target cancer cells more effectively, and it aims to help patients get better results than with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11062409 on NIH RePORTER |
What this research studies
This research focuses on developing innovative bispecific antibody-drug conjugates (ADCs) to treat metastatic prostate cancer. By targeting multiple tumor cell surface antigens simultaneously, the approach aims to enhance the effectiveness of treatment and improve drug delivery to cancer cells. The study builds on previous findings that identified specific antigens, such as CD46 and B7-H3, which are consistently expressed in prostate cancer. Patients may benefit from this targeted therapy, which could lead to better outcomes compared to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic prostate cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have the specific tumor antigens targeted by the bispecific ADCs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with similar bispecific antibody approaches in other cancers, indicating potential for success in this novel application.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Liu, Bin — University of California, San Francisco
- Study coordinator: Liu, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.